Abstract | PURPOSE: DESIGN: Review with editorial commentary. METHODS: A review of the medical literature and pertinent Internet postings combined with analysis of key studies with expert opinion regarding the use of aflibercept for the treatment of exudative age-related macular degeneration. RESULTS: CONCLUSIONS:
|
Authors | David J Browning, Peter K Kaiser, Philip J Rosenfeld, Michael W Stewart |
Journal | American journal of ophthalmology
(Am J Ophthalmol)
Vol. 154
Issue 2
Pg. 222-6
(Aug 2012)
ISSN: 1879-1891 [Electronic] United States |
PMID | 22813448
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- Angiogenesis Inhibitors
- Recombinant Fusion Proteins
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- aflibercept
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Angiogenesis Inhibitors
(pharmacokinetics, pharmacology, therapeutic use)
- Animals
- Clinical Trials as Topic
- Drug Approval
- Drug Evaluation, Preclinical
- Humans
- Macular Degeneration
(drug therapy)
- Receptors, Vascular Endothelial Growth Factor
- Recombinant Fusion Proteins
(pharmacokinetics, pharmacology, therapeutic use)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|